Trials / Completed
CompletedNCT02266628
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,599 (actual)
- Sponsor
- Novavax · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and immunogenicity of the RSV- F Vaccine in elderly subjects, as well as rate the incidence of medically- attended RSV disease in vaccine and placebo recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RSV-F Vaccine | |
| BIOLOGICAL | Saline Placebo |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-10-17
- Last updated
- 2022-05-27
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02266628. Inclusion in this directory is not an endorsement.